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Central serous chorioretinopathy (CSC) is a common disease
affecting younger people and may lead to vision loss. CSC shares
phenotypic overlap with age-related macular degeneration (AMD).
As recent studies have revealed a characteristic increase of choroidal
thickness in CSC, we conducted a genome-wide association study
on choroidal thickness in 3,418 individuals followed by TaqMan
assays in 2,692 subjects, and we identified two susceptibility loci:
CFH rs800292, an established AMD susceptibility polymorphism,
and VIPR2 rs3793217 (P = 2.05 × 10−10 and 6.75 × 10−8, respec-
tively). Case–control studies using patients with CSC confirmed
associations between both polymorphisms and CSC (P = 5.27 ×
10−5 and 5.14 × 10−5, respectively). The CFH rs800292 G allele is
reportedly a risk allele for AMD, whereas the A allele conferred
risk for thicker choroid and CSC development. This study not only
shows that susceptibility genes for CSC could be discovered using
choroidal thickness as a defining variable but also, deepens the un-
derstanding of differences between CSC and AMD pathophysiology.
GWAS | choroidal thickness | CFH | VIPR2 | central serous
chorioretinopathy
Central serous chorioretinopathy (CSC) constitutes a commoneye disease characterized by serous detachment of the cen-
tral retina (1). The incidence of CSC is reportedly around 10 per
100,000 in men and 2 per 100,000 in women (2). CSC can
spontaneously resolve, but 30–50% of cases become chronic and/
or recurrent, which results in severe retinal tissue damage and
permanent vision loss (3–5). Recent studies suggest that eyes
with CSC may be at higher risk of developing age-related mac-
ular degeneration (AMD) or its subtype of polypoidal choroidal
vasculopathy (PCV) even after spontaneous resolution of CSC
or that the development of CSC and AMD/PCV may share a
common background (6, 7).
Although the precise pathogenesis of CSC has not yet been
elucidated, genetic factors may contribute to CSC occurrence.
Familial clustering of CSC has been reported (8–10), and the
prevalence of CSC varies in different populations, being high in
Caucasians and Hispanics, with the highest prevalence reported
in Asians and an extremely low prevalence found in African
Americans; these differences may also reflect genetic predispo-
sition (11). To date, genome-wide association studies (GWASs)
have not reported any susceptibility genes for CSC. However,
three candidate gene studies have evaluated the established
AMD susceptibility gene CFH as a putative gene in CSC (12–
14). Notably, all reported that the CFH risk alleles associated
with AMD appeared as protective alleles for CSC, although
these two diseases might share pathophysiological overlap. There
is no clear explanation of why these alleles in CFH confer op-
posite effects in the development of AMD and CSC. Other than
CFH, no other susceptibility gene for CSC has been identified,
although some candidate gene studies reported possible genes of
interest (15–17).
Significance
Although central serous chorioretinopathy (CSC) presumptively
shares pathophysiological basis with age-related macular de-
generation (AMD), the CFH risk alleles for AMD are reportedly
protective against CSC development. Our finding, that the CFH
risk allele for AMD is protective against choroidal thickening in
a Japanese cohort, indicates that CFH affects CSC development
through its choroid-thickening effects rather than its association
with AMD, highlighting the need for a new AMD classification,
with CSC/pachychoroid-associated choroidal neovascularization
as a distinct disease. Furthermore, our genome-wide association
study (GWAS) addressing choroidal thickness successfully dis-
covered a susceptibility gene for CSC: VIPR2. Future GWASs on
choroidal thickness will likely discover additional CSC suscep-
tibility genes and provide key molecules to elucidate the
pathophysiological difference between CSC and AMD.
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Recent progress in imaging technology for use in the diagnosis
and monitoring of eye diseases has revealed that the choroid,
from where fluid leaks into the subretinal space to cause retinal
detachment in CSC, is thicker in eyes with CSC than in normal
eyes (18). This finding is in accordance with a previous sugges-
tion of choroidal vessel hyperpermeability in the pathogenesis of
CSC and that increased choroidal thickness is considered the
start of CSC development. Increased choroidal thickness is also
reported to be inherited (19). In this study, we performed GWAS
on choroidal thickness in a Japanese community-based cohort to
discover putative candidate genes, and using case–control stud-
ies, we further evaluated whether there was an association be-
tween these discovered genes and CSC development. We found
robust evidence of association of two susceptibility loci, rs800292
in CFH and rs3793217 in VIPR2, with choroidal thickness and
CSC development.
Results
Two-Stage GWAS for Choroidal Thickness. To investigate and identify
genetic loci associated with choroidal thickness, subfoveal cho-
roidal thickness in the right eye was used as the dependent vari-
able for genome-wide quantitative trait loci (QTL) analyses in
6,110 participants from the Nagahama Prospective Cohort for
Comprehensive Human Bioscience (the Nagahama Study) (SI
Appendix, Table S1). We included age, sex, axial length, and the
first principal component as covariates. A genomic inflation factor
lambda of 0.9991 indicated excellent control of the study pop-
ulation substructure (SI Appendix, Fig. S1).
For this two-stage GWAS, experiment-wide significance was set
at 5.0 × 10−8; additionally, we also tested SNPs with P values less
than 5.0 × 10−7 in the replication stage as findings indicative of
association. During the discovery stage using 4,710,779 SNPs from
3,418 participants, we identified genome-wide significant associ-
ation near the CFH locus with rs3753394 (P = 2.44 × 10−8) (Fig. 1
and Table 1) and indicative evidence of association at VIPR2 with
rs7782658 (P = 4.03 × 10−7). The respective SNP association plots
for the CFH and VIPR2 regions are shown in Figs. 2 and 3, re-
spectively. CFH rs3753394 was in moderate linkage disequilibrium
with rs800292, which is a widely known susceptibility SNP for
AMD (R2 = 0.721 in the discovery set). Because rs800292 also
showed strong association with choroidal thickness (P = 8.43 ×
10−8) in the discovery stage, we chose rs800292 as a candidate
SNP to be analyzed in the replication stage.
Conversely, for another putative susceptibility SNP, rs7782658
at the VIPR2 locus, a commercially designed TaqMan probe was
not available. Thus, to facilitate replication studies by other
groups, we sought SNPs in commercially available microarrays.
Among the VIPR2 SNPs found in both Illumina and Affymetrics
microarrays, rs3793217 had the strongest association with cho-
roidal thickness (P = 1.28 × 10−6) (Fig. 3). Because rs3793217
was in moderate linkage disequilibrium with rs7782658 (R2 =
0.605 in the discovery set), we analyzed rs3793217 in the repli-
cation stage (Fig. 3).
In the replication stage with 2,692 participants, both CFH
rs800292 and VIPR2 rs3793217 showed significant association
with choroidal thickness (P = 4.37 × 10−4 and P = 7.58 × 10−3,
respectively). Meta-analysis of the discovery and replication sets
further confirmed robust association of CFH rs800292 and
VIPR2 rs3793217 with choroidal thickness (P = 2.05 × 10−10 and
P = 6.75 × 10−8, respectively).
Association of CFH and VIPR2 with CSC. Next, the two SNPs iden-
tified during the GWAS for choroidal thickness, rs800292 in
CFH and rs3793217 in VIPR2, were evaluated to determine
whether they were associated with CSC in a Japanese case–
control study. We collected 701 DNA samples of patients with
CSC from five facilities in Japan, among which most of the
samples from Kobe University Hospital had already been tested
for an association between rs800292 and CSC (12). Thus, we
used 539 CSC cases from the four remaining facilities for the
case–control study of rs800292 by comparing its genotype dis-
tribution with that of the entire Nagahama cohort as a control
group. The genotype distribution of rs800292 did not signifi-
cantly deviate from Hardy–Weinberg equilibrium (HWE) in ei-
ther our cohort of patients with CSC or Nagahama controls
(both P > 0.05). In our test cohort, CFH rs800292 was associated
with CSC development (P = 5.27 × 10−5) (Table 2).
To test for association between VIPR2 and CSC, we used all
701 CSC DNA samples. We found that rs3793217 was in HWE
in both our CSC cohort and the Nagahama control cohort (P >
0.05) and that rs3793217 also showed significant association with
CSC development in the Japanese (P = 4.59 × 10−4) (Table 3).
Although the association between CFH and CSC has been
evaluated in other ethnicities (13, 14), an association between
VIPR2 and CSC had not been investigated. Therefore, we con-
ducted further replication analyses to test for evidence of an
association between rs3793217 and CSC in a Korean population.
In a case–control study using 425 patients with CSC and 1,643
controls, we found that rs3793217 showed significant association,
with an odds ratio similar to that found in the Japanese analysis
(P = 0.038). In addition, a meta-analysis using data from both
Fig. 1. Manhattan plots of the discovery-stage GWAS for subfoveal choroidal thickness. Each plot shows −log10(transformed P values) for all SNPs. The upper
horizontal line represents the genome-wide significance threshold of 5.0 × 10−8, and the lower horizontal line represents the indicative threshold of 5.0 × 10−7.
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ethnicity groups revealed additional support for an association
between VIPR2 rs3793217 and CSC (P = 5.14 × 10−5).
Association Between CFH and VIPR2 with Axial Length. Because
choroidal thickness becomes thinner in eyeballs with a longer
axial length (20), we next evaluated whether there was an asso-
ciation between rs800292 and rs3793217 with axial length in the
right eye using the entire Nagahama cohort. In our cohort of
6,110 participants, we found no association between either
rs800292 or rs3793217 with axial length (P = 0.074 and P = 0.30,
respectively) on linear regression analysis.
Association of Previously Reported Putative CSC Susceptibility Genes
with Choroidal Thickness and CSC in a Japanese Population. Of the
SNPs analyzed in the discovery stage, no SNPs in the C4B region
were associated with choroidal thickness (P > 0.05), although
significant associations between C4B genomic copy numbers and
CSC were previously reported (16). Within the regions of NR3C2
and CDH5, which are two previously reported putative suscep-
tibility genes for CSC (15, 17), rs10519952 in NR3C2 (P = 0.030)
showed nominally significant association with choroidal thick-
ness in our GWAS discovery stage (SI Appendix, Figs. S2 and
S3 and Table S2). However, no association was found for the
SNP with CSC development in our case–control study using 250
Japanese CSC samples genotyped with the HumanExome chip
and genome-wide genotyping data of 3,418 controls from the
Nagahama cohort (SI Appendix, Table S3).
Discussion
Our GWAS using a Japanese cohort identified two genes sig-
nificantly associated with choroidal thickness, CFH and VIPR2;
moreover, these genes were also significantly associated with the
occurrence of CSC in a Japanese case–control study. Although
CFH constitutes an established susceptibility gene for AMD and
three previous studies also reported an association between CFH
and CSC (12–14), no prior GWAS has investigated CFH in re-
lation to choroidal thickness. Furthermore, the conflicting report
that the CFH risk alleles for AMD were protective for CSC, two
diseases with a possible shared pathophysiological basis, has not
been clearly explained. Our GWAS discovery of a significant
association between CFH and choroidal thickness suggested that
CFH affects the occurrence of CSC via its effects on choroidal
thickness rather than via the previously suspected pathophysio-
logical overlap between CSC and AMD. In turn, our findings
regarding VIPR2 were supported by the replication of its asso-
ciation with CSC in a Korean cohort. Considering that the minor
allele frequency of VIPR2 rs3793217 is low in many ethnicities,
haplotype-tagged SNP analysis may be needed for further rep-
lication studies in other populations, which is warranted to de-
termine whether VIPR2 represents a common susceptibility gene
for CSC or is specific to Asian populations.
Using choroidal thickness in GWAS to discover susceptibility
genes for CSC is demonstrably warranted, because hyper-
permeability of choroidal vessels has been considered a strong
candidate as the main cause of CSC for over 50 y (21). Choroidal
hyperpermeability is predicted to result in a thicker choroid;
accordingly, recent progress in eye imaging technology has en-
abled us to confirm a thick choroid in the eyes of most patients
with CSC (18). Although some patients with CSC have a thinner
choroid than normal and not all eyes with a thicker choroid will
develop CSC, the discovery of two potential susceptibility genes
for CSC via GWAS for choroidal thickness supports the premise
that a thick choroid makes up at least one of the major con-
tributing factors in the development of CSC. Because recent
population-based cohort studies often included optical coher-
ence tomography (OCT) examination as part of their assess-
ment, meta-analysis of GWASs for choroidal thickness measured
by OCT may discover additional susceptibility genes for CSC.
The fact that not all eyes with a thicker choroid develop CSC
likely indicates that CSC develops via a multistep process. The
first step is increased choroidal thickness, which may confer
greater susceptibility to CSC, with a second step that may include
a trigger to cause CSC in those eyes with a thick choroid. Further
studies using CSC cohorts subgrouped by genes associated with
choroidal thickness may identify the genes associated with the
next step of CSC development as representing the trigger causing
CSC in eyes with a thicker choroid. Furthermore, as choroidal
structure is complex, GWASs for choroidal vessel thickening/
dilation, choroidal hyperpermeability, choroidal vascularity in-
dex, and choroidal thickness change in each individual might be
able to specify more genes associated with choroidal thickness
and CSC.
The discovery of genes associated with choroidal thickness and
CSC occurrence signifies that treatment strategies for CSC may
be developed by focusing on the mechanisms that underlie
thicker choroid. It is well-known that CFH is expressed in cho-
roidal vessels (22) and that VIPR2 is expressed in the retina and
choroid (23, 24). Pathways including CFH or VIPR2 may serve
as promising targets to treat CSC by controlling choroidal thickness.
Table 1. Discovery stage to identify SNPs associated with choroidal thickness
SNP CHR Position Effect allele EAF Nearby genes
Discovery stage Replication stage Meta-analysis
N β P N β P N β P
rs3753394 1 196620917 C 0.487 CFH (nearby) 3,418 11.84 2.44 × 10−8 — — — — — —
rs800292 1 196642233 A 0.406 CFH (in gene) 3,418 11.55 8.43 × 10−8 2,692 8.61 4.37 × 10−4 6,110 10.27 2.05 × 10−10
rs7782658 7 158858007 A 0.307 VIPR2 (in gene) 3,418 11.59 4.03 × 10−7 — — — — — —
rs3793217 7 158848821 G 0.213 VIPR2 (in gene) 3,418 12.46 1.28 × 10−6 2,692 7.69 7.58 × 10−3 6,110 10.34 6.75 × 10−8
CHR, chromosome; EAF, effect allele frequency in the discovery stage.
Fig. 2. Regional association plots for genotyped SNPs in CFH regions. Plots
represent the −log10(P values) obtained from the first-stage GWAS. Each P
value was calculated by age-, sex-, axial length-, and first principal compo-
nent-adjusted QTL analysis.






In addition, VIPR2 expression is up-regulated by Helicobacter
pylori infection, a known risk factor of CSC development (25,
26). Notably, the VIPR2 agonist vasoactive intestinal peptide can
control corticosteroid secretion in addition to its vasodilatory
effects in various vascular tissues (27–29). Further studies on
CFH and VIPR2 pathways are warranted to identify new treat-
ments for CSC.
An important factor in the interpretation of associations be-
tween CFH and VIPR2 with choroidal thickness and CSC is the
size of the eyeball as determined by axial length. A longer axial
length results in myopia (nearsightedness). Because choroidal
thickness is thinner in myopic eyeballs with a longer axial length
(20), we included axial length as an adjustment factor in our
GWAS on choroidal thickness. In fact, in addition to its associ-
ation with choroidal thickness and CSC occurrence, rs800292
showed indicative, but not significant, association with axial
length in our Japanese cohort (P = 0.073). Although VIPR2 did
not show significant association with axial length, two previous
studies in Chinese populations showed a significant association
between VIPR2 and axial length/myopia by evaluating other
SNPs in VIPR2 (23, 30). However, there were no previous re-
ports regarding the association of CFH with axial length/myopia,
and VIPR2 was not included as 1 of 51 major myopia-related
genes reported in large-scale GWASs for myopia using more
than 45,000 samples (31, 32), an omission that suggests that CFH
and VIPR2 have minor roles in myopia development. Both CFH
and VIPR2 may thus directly influence CSC occurrence by af-
fecting choroidal thickness rather than through their effect on
axial length.
In this study, we generated robust evidence that CFH consti-
tutes a susceptibility gene for CSC. Notably, CFH is also an
established susceptibility gene for AMD (22). Our previous study
showed that the G allele of rs800292 in CFH was a risk allele for
AMD with an odds ratio of 2.12 in the Japanese (33). In com-
parison, the rs800292 A allele was a risk allele for CSC with an
odds ratio of 1.30 in this study, with previous studies also
reporting the A allele as a risk allele for CSC with odds ratios of
1.66 and 1.50 in Japanese (12) and Caucasians (13), respectively.
We posit that the recent findings of choroidal thickness being
thinner in AMD and thicker in CSC (34) can be accounted for by
the effects of the rs800292 G allele toward reducing choroidal
thickness in AMD and the A allele toward promoting thicker
choroid in CSC.
The possibility of a pathophysiological overlap between CSC
and AMD has facilitated analyses toward identifying associations
between CSC and AMD (6) or between CSC and AMD sus-
ceptibility genes (13). However, an overlap between the patho-
physiology of these diseases cannot explain the opposing effects
conferred by the same genetic polymorphisms in the respective
development of CSC and AMD. Recently, another theory was
proposed that a thick choroid, termed pachychoroid from the
ancient Greek, serves as a common background of CSC and an
AMD-like disorder that should be distinguished from AMD
named pachychoroid neovasculopathy (PCN) (35). Thus, the
seemingly contrasting findings between CFH and AMD vs. CFH
and CSC/thick choroid in our study would support the need to
distinguish pachychoroid and PCN from AMD in clinical settings,
with the premise that PCN and AMD have different underlying
pathophysiologies. Currently, a clear definition to differentiate
PCN from AMD has not yet been established, because PCN
shares many clinical characteristics with AMD. Further genetic
studies using choroidal thickness, CSC, PCN, and AMD may
reveal the detailed underlying relationships of these three dis-
eases and enable tailored treatment strategies in the future.
Candidate gene studies previously reported that SNPs in
CDH5 and NR3C2 and gene copy number variations in C4B, but
not SNPs, were significantly associated with CSC development
(15–17). In our GWAS discovery cohort, we found that no SNPs
or indels in C4B and CDH5 showed significant association with
choroidal thickness. Although an SNP in NR3C2 (P = 0.030)
showed nominally significant associations with choroidal thick-
ness, it was not significantly associated with CSC development.
Furthermore, because the allele effects were opposite from those
found in the original report, we concluded that CDH5 and
NR3C2 do not make up susceptibility genes for CSC in our
Japanese population.
In conclusion, using GWAS, we identified significant associ-
ations between CFH and VIPR2 with choroidal thickness and
robustly showed significant associations of CFH and VIPR2 with
the development of CSC. Based on our findings, we propose that
CFH and VIPR2 contribute to the pathogenesis of CSC via their
effects on choroidal thickness. Our findings also indicate that the
difference in choroidal thickness found between CSC and AMD,
where CSC has a thicker choroid and AMD has a thinner cho-
roid, may be accounted for by genetic differences between the
two diseases. Our genetic study thus provides the basis for un-
derstanding the roles of choroidal thickness in CSC and AMD.
Methods
Study Participants for the Choroidal Thickness GWAS. The study population
consisted of healthy Japanese volunteers enrolled in the Nagahama Study.
Participants were recruited between 2008 and 2010 from the general population
of Nagahama in Japan (36, 37). Community residents living independently
Fig. 3. Regional association plots for genotyped SNPs in VIPR2 regions. Plots
represent the −log10(P values) obtained from the first-stage GWAS. Each P
value was calculated by age-, sex-, axial length-, and first principal compo-
nent-adjusted QTL analysis.
Table 2. Association between CFH rs800292 and CSC in the Japanese
Ethnicity Major/minor allele
Control CSC
Odds ratio (95% CI) P*N MAF N MAF
Japanese G/A 6,110 0.401 539 0.464 1.29 (1.14–1.47) 5.27 × 10−5
MAF, minor allele frequency.
*P values derived using χ2 test.
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and without physical impairment or dysfunction were eligible. Blood sam-
pling was performed at the time of enrollment. Of the 9,804 recruited
participants, 14 withdrew consent to participate, and 26 were excluded,
because genetic analysis indicated an ethnic background other than Japa-
nese. Participants were offered physical and ophthalmic evaluation 5 y after
the baseline evaluation from 2013 to 2015, and 8,289 of the original
9,764 cohort members, ages between 34 and 80 y old, participated.
In the follow-up assessment, all subjects underwent ophthalmic exami-
nations, including an objective determination of the refractive error and
corneal curvature using an Autorefractor ARK-530 (Nidek), axial length
measurements by partial coherence interferometry with an IOL Master (Carl
Zeiss Meditec, Inc.), color fundus imaging using a CD-DG10 (Canon), and a
cross-line scan of spectral domainOCT examination using an RS-3000 Advance
(Nidek) with an enhanced depth imaging (EDI) technique.
In this study, we used a dataset of the follow-up measurements. Study
subjects consisted of individuals with available DNA samples as well as age,
sex, axial length, fundus imaging, and OCT data. Exclusion criteria included
prior intraocular surgery (except for cataract surgery), laser photocoagula-
tion, and the presence of other macular-involving diseases that may affect
choroidal thickness, such as active CSC, neovascular AMD, dry AMD with
geographic atrophy, retinal vein occlusion, retinoschisis, macular hole, focal
choroidal excavation, drusen, retinal pigment epithelium (RPE) damage,
pigment epithelium detachment, or macular edema. Subjects with poor-quality
images of fundus OCT were excluded. Highly myopic samples with axial
length longer than 26 mm were also excluded from analysis.
The Kyoto University Graduate School and Faculty of Medicine Ethics Com-
mittee and the Nagahama Municipal Review Board of Personal Information
Protection approved the study protocol andprocedures used to obtain informed
consent. All study procedures adhered to the tenets of the Declaration of
Helsinki. All participants were fully informed regarding the purpose and pro-
cedures of the study, and written consent was obtained from each subject.
Patient records and information were anonymized before analysis.
Evaluation of Choroidal Thickness. Images of the foveal line EDI OCT scans
centered on the fovea in right eyes were used tomeasure choroidal thickness.
The choroidal–scleral interface was defined manually as the hyperreflective
line behind the large choroidal vessel layers, and choroidal thickness was
automatically measured between the RPE line and the choroidal–scleral in-
terface at 1,024 points along the horizontal and vertical scans. The average
thickness of points 512 and 513 on both scans was defined as the subfoveal
choroidal thickness.
Genome-Wide SNP Genotyping and Statistical Analysis. Genome-wide QTL
analysis was performed using subfoveal choroidal thickness in the discovery
set of the Nagahama cohort. For every SNP that passed quality control, we
evaluated whether there was an association between genotype and sub-
foveal choroidal thickness using a multivariable linear regression, assuming
an additive model. This regression framework allowed us to adjust for
covariates, such as age, sex, axial length, and the first principal component.
Genome-wide SNP genotyping was performed on samples from 5,324 par-
ticipants who joined the Nagahama cohort from 2008 to 2009. A series of
BeadChip DNA arrays (Illumina), namely HumanHap610 Quad (1,833 sam-
ples), HumanOmni2.5–4 (1,611 samples), HumanOmni2.5–8 (375 samples),
HumanOmni2.5s (670 samples), CoreExome24 (1,727 samples), and HumanExome
(670 samples), were used for the analysis. SNPs with a call rate <99%, a
minor allele frequency <1%, or significant deviation (P < 1.0 × 10−6) from
HWE were excluded from further statistical analysis. Samples with a call
rate <95% were also excluded from the analysis. Subjects estimated to have
a first or second degree kinship within this population (pi-hat > 0.35) were
removed. Samples with genetic analysis that showed an ethnic background
other than Japanese were also excluded. Among the remaining subjects,
4,192 individuals were followed 5 y after the baseline evaluation from
2013 to 2015 (SI Appendix, Fig. S4). Genotype imputation was performed
using MACH (www.sph.umich.edu/csg/abecasis/MACH/tour/imputation.html)
with the 1000 Genomes phase 3 v5 release dataset as a reference panel.
Imputed SNPs with R2 < 0.5 were excluded from the association analysis.
Finally, 4,710,779 SNPs from 3,418 individuals were used for the discovery-
stage analysis; 83 samples without sufficient quality EDI OCT images,
54 samples with macular-involving diseases, 49 samples lacking the data of
axial length, 237 samples with intraocular surgery or laser photocoagulation,
and 351 samples with axial length >26 mm were excluded.
Experiment-wide significance was set at 5.0 × 10−8. We also tested SNPs
with P values less than 5.0 × 10−7 in the replication stage as findings of in-
dicative association. Statistical analyses were performed with R version 3.2.5
(R Foundation for Statistical Computing; available at https://www.R-project.
org/) and PLINK version 1.9 (https://www.cog-genomics.org/plink2).
Replication Genotyping for the Association Study on Choroidal Thickness. In the
replication stage using the remaining samples from the Nagahama cohort,
rs800292 and rs3793217 were genotyped using TaqMan allelic discrimination
probes (Applied Biosystems) with an ABI PRISM 7700 system (Applied Bio-
systems). Deviations in genotype distributions from HWE were assessed with
the χ2 test. To determine whether there was an association between
rs800292 and rs3793217 with choroidal thickness, the subfoveal choroidal
thickness in the right eye was used as the dependent variable for multi-
variable linear regression analysis, including age, sex, and axial length
as covariates.
To replicate our findings from the GWAS of choroidal thickness, we used
2,692 samples from the remaining 3,314 individuals of the Nagahama Study;
two samples with withdrawn consent, 94 samples without sufficient quality
EDI OCT images, 44 samples with macular-involving diseases, 83 samples
lacking the data of axial length, 135 samples with intraocular surgery or laser
photocoagulation, and 264 samples with axial length >26 mm were ex-
cluded. A P value <0.05 was considered statistically significant.
Diagnosis of Patients with CSC.We recruited 701 unrelated Japanese patients
with acute, chronic, or steroid-induced CSC from the Kyoto University Hos-
pital, the Kobe University Hospital, the Yamanashi University Hospital, the
Fukushima Medical University Hospital, and the Kagawa University Hospital.
All procedures adhered to the tenets of the Declaration of Helsinki. The
institutional review boards and the ethics committees of the participating
institutions approved the study protocols. All patients were fully informed of
the purpose and procedures of the study, and written consent was received
from each patient before their participation in the study.
All of the patients underwent a comprehensive ophthalmic examination,
including dilated funduscopy, color fundus photography, OCT examination
including EDI, fundus autofluorescence (FAF), fluorescein angiography (FA),
and indocyanin green angiography (ICGA). CSC was diagnosed as an eye with
subretinal fluid at the macular region on OCT together with a leakage on FA
and choroidal vascular hyperpermeability on ICGA. Eyes with AMD or PCV
were excluded. Eyes with RPE damage or atrophic dependent tracks on FA or
FAF and choroidal vascular hyperpermeability on ICGA were included as eyes
with “inactive CSC,” despite an absence of documented subretinal fluid (38–41).
Association with CSC Development.We genotyped 250 of the 701 CSC samples
using the HumanExome chip, and the genotypes of rs800292, rs3793217, and
rs7499886 were directly determined from the chip. The genotypes of
rs3837775, rs10519952, and rs2075951 were determined by imputation using
the Michigan imputation server (https://imputationserver.sph.umich.edu/
index.html) with the 1000 Genomes phase 3 v5 release dataset as a refer-
ence panel (42, 43). For the remaining 451 CSC samples, rs800292 and/or
rs3793217 were genotyped using the TaqMan SNP assay. In the case–control
study, the discovery and replication sets of the Nagahama cohort were used
as control subjects. Deviations in genotype distributions from HWE were
Table 3. Association between VIPR2 rs3793217 and CSC
Ethnicity Major/minor allele
Control CSC
Odds ratio (95% CI) P*N MAF N MAF
Japanese A/G 6,110 0.213 701 0.254 1.26 (1.11–1.43) 4.59 × 10−4
Korean A/G 1,643 0.201 425 0.234 1.21 (1.01–1.45) 0.038
Meta — 7,753 — 1,126 — 1.24 (1.12–1.38) 5.14 × 10−5
MAF, minor allele frequency.
*P values derived using χ2 test.






assessed in the CSC cohort with the χ2 test. The χ2 test for trend or its exact
counterpart was used to compare the genotype distributions between two
groups. A P value ≤ 0.05 was considered statistically significant.
Replication Study for Association of VIPR2 rs3793217 with CSC in Koreans. We
recruited 425 unrelated Korean patients with acute or chronic CSC at the
Seoul National University Bundang Hospital (SNUBH) retina clinic. Control
samples consisted of subjects recruited from visitors to the SNUBH healthcare
center for regular medical checkups or from patients undergoing cataract
surgery at the SNUBH retina clinic (n = 310). Control subjects were also
participants of the Korean Longitudinal Study on Health and Aging (KLoSHA;
n = 233) (44) and were from the Korean Reference Genome database (n =
1,100; available at 152.99.75.168/KRGDB). All procedures adhered to the
tenets of the Declaration of Helsinki. The institutional review boards and the
ethics committees of the institutions approved the study protocols. All
participants were fully informed of the purpose and procedures of the study,
and written consent was received from each participant. Patients with CSC
were genotyped using the TaqMan SNP assay (Applied Biosystems), and
controls from the SNUBH and the KLoSHA were genotyped with the
OmniExpress array (Illumina). The genotypes of rs3793217 were directly
determined from the chip.
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